EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical Whole-Genome Sequencing Assay for Rapid Mycobacterium tuberculosis Complex First-Line Drug Susceptibility Testing and Phylogenetic Relatedness Analysis

Bennett Shaw, Benjamin von Bredow iD, Allison Tsan, Omai Garner, Shangxin Yang iD

Microorganisms · 11.10.2023 · 11 (10) · 2538

DOI: 10.3390/microorganisms11102538 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microorganisms, online erschienen am 11.10.2023. Verfasst von Bennett Shaw und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA 90095, USA. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UCLA Department of Pathology and Laboratory Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The global rise of drug resistant tuberculosis has highlighted the need for improved diagnostic technologies that provide rapid and reliable drug resistance results. Here, we develop and validate a whole genome sequencing (WGS)-based test for identification of mycobacterium tuberculosis complex (MTB) drug resistance to rifampin, isoniazid, pyrazinamide, ethambutol, and streptomycin. Through comparative analysis of drug resistance results from WGS-based testing and phenotypic drug susceptibility testing (DST) of 38 clinical MTB isolates from patients receiving care in Los Angeles, CA, we found an overall concordance between methods of 97.4% with equivalent performance across culture media. Critically, prospective analysis of 11 isolates showed that WGS-based testing provides results an average of 36 days faster than phenotypic culture-based methods. We showcase the additional benefits of WGS data by investigating a suspected laboratory contamination event and using phylogenetic analysis to search for cryptic local transmission, finding no evidence of community spread amongst our patient population in the past six years. WGS-based testing for MTB drug resistance has the potential to greatly improve diagnosis of drug resistant MTB by accelerating turnaround time while maintaining accuracy and providing additional benefits for infection control, lab safety, and public health applications.

Schlagwörter

Stichwörter der Autor:innen

Mycobacterium tuberculosis complexclinical evaluationdrug susceptibility testingphylogenetic relatedness analysiswhole-genome sequencing

Autor:innen und Institutionen

  • Department of Pathology and Laboratory Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA 90095, USA.
  • Department of Pathology, Oakland University William Beaumont School of Medicine, Rochester, MI 48309, USA.

ORCID-Profile: Benjamin von Bredow, Shangxin Yang

Förderung

  • UCLA Department of Pathology and Laboratory Medicine

Zitieren

APA

Shaw, B., von Bredow, B., Tsan, A., Garner, O., & Yang, S. (2023). Clinical Whole-Genome Sequencing Assay for Rapid Mycobacterium tuberculosis Complex First-Line Drug Susceptibility Testing and Phylogenetic Relatedness Analysis. Microorganisms, 11(10), 2538. https://doi.org/10.3390/microorganisms11102538

Vancouver

Shaw B, von Bredow B, Tsan A, Garner O, Yang S. Clinical Whole-Genome Sequencing Assay for Rapid Mycobacterium tuberculosis Complex First-Line Drug Susceptibility Testing and Phylogenetic Relatedness Analysis. Microorganisms. 2023;11(10):2538. doi:10.3390/microorganisms11102538

BibTeX
@article{Shaw2023,
  author = {Shaw, Bennett and von Bredow, Benjamin and Tsan, Allison and Garner, Omai and Yang, Shangxin},
  title = {Clinical Whole-Genome Sequencing Assay for Rapid Mycobacterium tuberculosis Complex First-Line Drug Susceptibility Testing and Phylogenetic Relatedness Analysis},
  journal = {Microorganisms},
  year = {2023},
  volume = {11},
  number = {10},
  pages = {2538},
  doi = {10.3390/microorganisms11102538}
}
Kostenlos starten →